Compare · CI vs YDES
CI vs YDES
Side-by-side comparison of The Cigna Group (CI) and YD Bio Limited (YDES): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and YDES operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $72.64B, about 188.6x YDES ($385.0M).
- Over the past year, CI is down 17.7% and YDES is down 60.7% - CI leads by 43.0 points.
- CI has been more active in the news (14 items in the past 4 weeks vs 1 for YDES).
- CI has more recent analyst coverage (25 ratings vs 0 for YDES).
- Company
- The Cigna Group
- YD Bio Limited
- Price
- $275.55-1.49%
- $5.25+4.79%
- Market cap
- $72.64B
- $385.0M
- 1M return
- +1.90%
- -33.59%
- 1Y return
- -17.71%
- -60.70%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 14
- 1
- Recent ratings
- 25
- 0
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Latest CI
- Director Foss Eric J was granted 782 shares, increasing direct ownership by 2% to 36,696 units (SEC Form 4)
- Director Mcclellan Mark B. was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Zarcone Donna F was granted 782 shares, increasing direct ownership by 3% to 27,517 units (SEC Form 4)
- Director Hathi Neesha was granted 782 shares, increasing direct ownership by 23% to 4,151 units (SEC Form 4)
- Director Mazzarella Kathleen M was granted 782 shares, increasing direct ownership by 13% to 6,891 units (SEC Form 4)
- Director Kurian George was granted 782 shares, increasing direct ownership by 21% to 4,560 units (SEC Form 4)
- Director Ross Kimberly A. was granted 782 shares, increasing direct ownership by 17% to 5,294 units (SEC Form 4)
- Director Hennigan Michael J was granted 782 shares, increasing direct ownership by 138% to 1,350 units (SEC Form 4)
- Director Ozuah Philip was granted 782 shares, increasing direct ownership by 43% to 2,583 units (SEC Form 4)
- Director Wiseman Eric C was granted 782 shares, increasing direct ownership by 3% to 23,940 units (SEC Form 4)
Latest YDES
- Amendment: SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 4 filed by Lu Shao-Ta
- SEC Form 4 filed by Chang Kochi
- SEC Form 3 filed by new insider Lu Shao-Ta
- SEC Form 3 filed by new insider Chang Kochi
- YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
- SEC Form 3 filed by new insider Lee Jerry Yin-Chia
- SEC Form 3 filed by new insider Zhang Bo-Xiang
- SEC Form 3 filed by new insider Hen Man Edmund
- SEC Form 3 filed by new insider Shen Ethan Phd